Evidence map›Paper›PMID 35019939›Full record

ArticleJAMA dermatology2022

Interventions for Cutaneous Disease in Systemic Lupus Erythematosus: Summary of a Cochrane Review.

Grant Sprow, Mohsen Afarideh, Victoria P Werth

Abstract readComment
PubMed Publisher
In one paragraph

Article in JAMA dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Grant SprowCorporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia.
Mohsen AfaridehCorporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia.
Victoria P WerthCorporal Michael J. Crescenz Veterans Affairs Medical Center, Department of Dermatology, University of Pennsylvania, Philadelphia.
Philadelphia VA Medical Center · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

clinical questionWhat is the efficacy of interventions for cutaneous disease in systemic lupus erythematosus (SLE) in randomized clinical trials (RCTs)? BOTTOM LINE: Available RCT evidence on the management of cutaneous disease in SLE is sparse and of limited quality. Among traditional options, methotrexate and hydroxychloroquine have the strongest evidence compared with placebo in the end points of complete clinical response and number of clinical flares, respectively, while chloroquine appears noninferior to methotrexate in achieving complete clinical response.

Indexed as

Lupus Erythematosus, SystemicSkin DiseasesChloroquineHumansHydroxychloroquineChloroquineHydroxychloroquine

Identifiers

PMID35019939
OpenAlexW4206117406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.